Skip to main content Accessibility help
×
×
Home

Medicinal Marijuana for Epilepsy: A Case Series Study

  • Lady Diana Ladino (a1) (a2), Lizbeth Hernández-Ronquillo (a1) and José Francisco Téllez-Zenteno (a1)
Abstract

Objective: To describe the social, clinical and use-patterns characteristics of medicinal marijuana use among patients with epilepsy (PWEs). Methods: Eighteen PWEs with prescriptions for medicinal marijuana from a Canadian adult-epilepsy clinic were included in this study. Results: Eighteen patients had a prescription of medicinal marijuana from a total population of 800 PWEs in our center (2.2%). Mean age of patients was 30±7.4 (19-50) years. Twelve (67%) patients were males. Eleven (61%) patients had drug-resistant epilepsy. Eleven (61%) patients suffered a psychiatric comorbidity and reported the use of illicit substances or heavy alcohol or tobacco consumption. Only two (11%) patients were married; the rest of patients (89%) were single or divorced. The drug use pattern was similar among patients. All patients asked for marijuana permission in the epilepsy clinic. Most (83%) had a previous history of marijuana smoking, with a mean of 6.6±3 (1-15) years. The mean consumption dose was 2.05±1.8 (0.5-8) grams per day. Ten (56%) patients reported withdrawal seizure exacerbation when they stopped the marijuana. Only two patients (11%) reported side effects, and all patients found medicinal marijuana very helpful for seizure control and improvement of mood disorder. Conclusions: PWEs using medicinal marijuana have a common profile. They are usually young single men with drug-resistant epilepsy and psychiatric comorbidity. Most used marijuana before formal prescription and all believe the drug was effective on their seizure control. Because of the concurrent use of other antiseizure medications, it is complex to estimate the actual effect of marijuana.

La marijuana médicinale contre l’épilepsie : étude d’une série de cas. Objectif: Détailler les caractéristiques sociales, cliniques et d’utilisation de la marijuana médicinale chez les patients atteints d’épilepsie. Méthodes: Dix-huit patients atteints d’épilepsie ayant des ordonnances de prescriptions de marijuana médicinale délivrées par une clinique canadienne d’épilepsie de l’adulte ont été inclus dans cette étude. Résultats: Sur une population totale de 800 patients atteints d’épilepsie et suivis dans notre centre, 18 (2,2%) avaient une ordonnance de marijuana médicinale. L’âge moyen des patients était de 30 ± 7,4 (19-50) ans. Douze (67%) patients étaient des hommes. Onze (61%) patients avaient une épilepsie résistante aux médicaments. Onze (61%) patients souffraient d’une comorbidité psychiatrique et avaient signalé l’utilisation de substances illicites ou une forte consommation d’alcool ou de tabac. Seuls, deux (11%) patients étaient mariés; les autres patients (89%) étaient célibataires ou divorcés. Les caractéristiques d’utilisation des drogues étaient similaires pour tous les patients. Tous les patients ont demandé la permission de consommation de marijuana à la clinique d’épilepsie. La majorité d’entre eux (83%) avaient des antécédents de consommation de marijuana depuis, en moyenne, 6,6 ± 3 (1-15) ans. La dose moyenne consommée était de 2,05 ± 1,8 (0,5-8) grammes par jour. Dix (56%) patients ont décrit une exacerbation de sevrage des crises convulsives lorsqu’ils ont arrêté la marijuana. Seulement deux patients (11%) ont signalé des effets indésirables et tous les patients ont trouvé que la marijuana médicinale était très utile pour le contrôle des crises et l’amélioration des troubles de l’humeur. Conclusions: Les patients atteints d’épilepsie utilisant de la marijuana médicinale ont un profil commun. Ils sont habituellement jeunes, célibataires, atteints d’une épilepsie résistant aux médicaments et ils ont une comorbidité psychiatrique. La majorité d’entre eux utilisait la marijuana avant une ordonnance officielle et tous croient que la drogue est efficace pour le contrôle de leur crise. Compte tenu de l’utilisation concomitante d’autres médicaments antiépileptiques, il est difficile d’évaluer l’effet véritable de la marijuana.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Medicinal Marijuana for Epilepsy: A Case Series Study
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Medicinal Marijuana for Epilepsy: A Case Series Study
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Medicinal Marijuana for Epilepsy: A Case Series Study
      Available formats
      ×
Copyright
Corresponding author
Correspondence to: José Francisco Téllez-Zenteno, Division of Neurology, Department of Medicine, Royal University Hospital, 103 Hospital Drive, Box 26, Room 1622, Saskatoon, SK. S7N OW8 Canada. Email: jose.tellez@usask.ca
References
Hide All
1. Ben Amar, M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.
2. Wilson, RI, Nicoll, RA. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature. 2001;410:588-592.
3. Wingerchuk, D. Cannabis for medical purposes: cultivating science, weeding out the fiction. Lancet. 2004;364(9431):315-316.
4. Wallace, R. Cannabinoids: defending the epileptic brain. Epilepsy Curr. 2004;4(3):93-95.
5. Ghosh, P, Bhattacharya, SK. Anticonvulsant action of cannabis in the rat: role of brain monoamines. Psychopharmacology (Berl). 1978;59(3):293-297.
6. Santry, C. Canadian doctors say it is inappropriate for them to prescribe marijuana. BMJ. 2012;345:e8623.
7. Health Canada government website. Harper government announces new marihuana for medical purposes regulations: Changes improve public safety and maintain patient access. [Updated 2013 Jun 10]. Available from: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2013/2013-79-eng.php.
8. Health Canada government website. Drug and health products: medical use of marihuana. About the marijuana medical access program. [Updated 2013 Jun 20]. Available from: http:// http://www.hc-sc.gc.ca/dhp-mps/marihuana/about-apropos/index-eng.php.
9. Justice Laws Website. Marijuana Medical Access Regulations SOR/2001-227. [Updated 2013 December 9]. Available from: http://laws-lois.justice.gc.ca/eng/regulations/SOR-2001-227/page-2.html#s-5.
10. Saskatoon.ca. City of Saskatoon neighborhood profiles. 2011 census/2012 estimates/demographic and housing data. [Updated 2012 July 9]. Available from: http://www.saskatoon.ca/DEPARTMENTS/Community%20Services/PlanningDevelopment/Documents/Research/Neighbourhood_profiles/2012/Neighbourhood%20Profiles.pdf.
11. Government of Canada website. Statistics Canada. Median total income, by family type, by province and territory (all census families). [Updated 2012 February 8]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/famil108a-eng.htm.
12. City–Data.com. Saskatchewan agglomerations, cities, towns and villages. The median total income before taxes. [Updated 2013 March]. Available from: http://www.city-data.com/canada/Saskatchewan-Index.html.
13. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389-399.
14. Kwan, P, Arzimanoglou, A, Berg, AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077.
15. Gloss, D, Vickrey, B.. Cannabinoids for epilepsy. Cochrane Database of Systematic Reviews. 2012;6:CD009270.
16. Chan, GC, Hinds, TR, Impey, S, Storm, DR. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci. 1998;18(14):5322-5332.
17. Feeney, DM. Marijuana use among epileptics. JAMA. 1976;235(11):1105.
18. Walsh, Z, Callaway, R, Belle-Isle, L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24(6):511-516.
19. Ogborne, AC, Smart, RG. Cannabis users in the general Canadian population. Subst Use Misuse. 2000;35(3):301-311.
20. Lucas, P. It can't hurt to ask; a patient-centered quality of service assessment of health Canada's medical cannabis policy and program. Harm Reduct J. 2012;9:2-11.
21. Hamerle, M, Ghaeni, L, Kowski, A, Weissinger, F, Holtkamp, M. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol. 2014;21(1):167-170.
22. Gross, DW, Hamm, J, Ashworth, NL, Quigley, D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology. 2004;62(11):2095-2097.
23. Gordon, E, Devinsky, O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42:1266-1272.
24. Hegde, M, Santos-Sanchez, C, Hess, CP, Kabir, AA, Garcia, PA. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav. 2012;25(4):563-566.
25. Karler, R, Calder, LD, Turkanis, SA. Prolonged CNS hyperexcitability in mice after a single exposure to delta-9tetrahydrocannabinol. Neuropharmacology. 1986;25:441-446.
26. Sirven, JI, Drazkowski, JF, Zimmerman, RS, Bortz, JJ, Shulman, DL, Macleish, M. Complementary/alternative medicine for epilepsy in Arizona. Neurology. 2003;61(4):576-577.
27. Easterford, K, Clough, P, Comish, S, Lawton, L, Duncan, S. The use of complementary medicines and alternative practitioners in a cohort of patients with epilepsy. Epilepsy Behav. 2005;6(1):59-62.
28. Smith, GW, Farrell, M, Bunting, BP, Houston, JE, Shevlin, M. Patterns of polydrug use in Great Britain: findings from a national house-hold population survey. Drug Alcohol Depend. 2011;113:222-228.
29. Connor, JP, Gullo, MJ, Chan, G, Young, RM, Hall, WD, Feeney, GF. Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs. Front Psychiatry. 2013;4(79):1-7.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Neurological Sciences
  • ISSN: 0317-1671
  • EISSN: 2057-0155
  • URL: /core/journals/canadian-journal-of-neurological-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed